Shares of Vericel Corp. (NASDAQ:VCEL) were up 2.9% on Friday . The company traded as high as $2.18 and last traded at $2.15, with a volume of 74,618 shares. The stock had previously closed at $2.09.

A number of analysts have weighed in on VCEL shares. Needham & Company LLC restated a “buy” rating and set a $12.00 target price on shares of Vericel Corp. in a report on Tuesday, April 5th. Bank of America Corp. lowered Vericel Corp. from a “buy” rating to a “neutral” rating in a report on Tuesday, April 5th.

The firm has a 50 day moving average price of $2.39 and a 200-day moving average price of $2.79. The company’s market capitalization is $49.81 million.

Vericel Corp. (NASDAQ:VCEL) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.17. The firm had revenue of $14.10 million for the quarter, compared to analysts’ expectations of $11.60 million. Equities research analysts forecast that Vericel Corp. will post ($0.79) EPS for the current year.

Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc develops patient-specific expanded cellular therapies for use in the treatment of patients with diseases and conditions. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns greater than or equal to 30% of total body surface area (TBSA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.